ADVANCED BLOOD-BASED MOLECULAR TESTING
A Blood Test for Earlier Insight Into Cancer-Related Activity
Liquid RNA analyzes active gene expression from a simple blood sample: looking for molecular patterns associated with cancer activity, treatment response and recurrence monitoring, alongside broader biological signals.
For people living with cancer, people who have completed treatment, and people seeking additional molecular information.
Pricing: Canada C$5,300 + GST | USA US$3,900
Research-based and informational. Liquid RNA complements - but does not replace - recommended screening, imaging, pathology, diagnosis or care from a licensed physician.
What do you want to understand?
Could something be changing before it appears on a scan?
Explore molecular signals that may support a more informed conversation with your care team.
Is treatment changing the biology?
Follow changes in active gene expression over time to add context to treatment-response monitoring.
Could cancer-related activity be returning?
Add another layer of molecular information between standard follow-up appointments.
Liquid RNA can also report on broader biological pathways, including immune and inflammatory signalling. Findings require appropriate clinical interpretation.
WHY RNA SEQUENCING
DNA can show what changed. RNA can show what is active.
Understanding cancer biology requires looking beyond static genomic alterations. While DNA provides the baseline blueprint of mutations, RNA reveals dynamic, real-time cellular signalling and active gene transcription.
DNA SEQUENCING
DNA
Identifies genetic changes that may be present.
DNA testing reveals inherited risk factors, baseline structural alterations, and permanent mutations in the genome. It provides essential context on what alterations exist within tumor cells.
RNA SEQUENCING
RNA
Measures which genes are actively being transcribed now.
RNA analysis evaluates active cellular transcription, monitoring which pathways are switched on or off in real time. It offers direct insight into ongoing biological behaviour and dynamic response.
WHOLE-TRANSCRIPTOME VIEW
Liquid RNA uses a 20,814 gene transcriptions panel to provide a broad view of active biological signalling.
By evaluating active gene expression across thousands of transcripts from a simple blood sample, Liquid RNA offers comprehensive insight into ongoing cellular dynamics, immune signalling, and active pathways without invasive tissue procedures.
WHO IT'S FOR
Built for the questions people actually have
Liquid RNA provides research-based molecular insights tailored to where you are in your healthcare journey.
Living with cancer
Additional molecular context alongside treatment and imaging to help track active gene expression signals over time.
After treatment
Additional information for recurrence monitoring and survivorship discussions with your clinical care team.
Proactive about health
Broader molecular insight to discuss with a qualified healthcare professional, exploring active biological pathways.
Careful molecular profiling designed to inform collaborative discussions with your healthcare team with no guarantee of early detection.
WHAT THE REPORT CAN EXPLORE
Comprehensive Whole-Transcriptome Analysis
Liquid RNA evaluates active gene expression across 20,814 gene transcriptions from a simple blood sample to explore multi-dimensional molecular insights.
Cancer-Associated Molecular Activity
Measures active transcriptional signals and gene expression patterns associated with cancer-related cellular activity.
Treatment-Response Patterns
Tracks changes in active gene expression over time to provide additional biological context for treatment-response monitoring.
Recurrence-Associated Changes
Adds an informative molecular layer between standard follow-up appointments and routine clinical evaluations.
Immune & Inflammatory Signalling
Surveys broader biological pathways, including microenvironment dynamics, immune response activity, and inflammatory pathways.
HER2-Related Expression
Analyzes transcription levels of HER2 and relevant growth-factor signalling cascades to provide targeted biomarker information.
Other Active Biological Pathways
Evaluates complex biological networks across the 20,814 gene transcriptions panel to provide a wide, informative view of ongoing activity.
IMPORTANT CLINICAL CONTEXT
Not every finding is clinically actionable. Results must be considered alongside medical history and standard clinical testing. Liquid RNA complements—but does not replace—recommended screening, imaging, pathology, or care from a licensed physician.
HOW IT WORKS
Four Steps to Molecular Insight
A straightforward, structured process designed to provide comprehensive whole-transcriptome molecular information from a simple blood draw.
Tell us what you want to understand
Complete a short, no-obligation enquiry to share your goals and questions.
Arrange blood collection
Collection options and kit logistics are coordinated with you.
Whole-transcriptome analysis
The laboratory analyzes the 20,814 gene transcriptions panel.
Receive your report
Results are provided in approximately three weeks after the sample arrives at the laboratory.
RESEARCH & OBSERVATIONAL DATA
Research-informed. Transparently presented.
We share clinical and observational data openly, ensuring clarity regarding cohort context, methodology, and informational boundaries.
BREAST & LUNG
Observed Cohort Performance
Breast — Sensitivity 100% | Specificity 87.5% | Accuracy 97.1% | ROC-AUC 0.93
Lung — Sensitivity 100% | Specificity 88.9% | Accuracy 94.4% | ROC-AUC 0.94
PROSTATE & GASTROINTESTINAL
Observed Cohort Performance
Prostate — Sensitivity 100% | Specificity 88.9% | Accuracy 94.1% | ROC-AUC 0.93
Gastrointestinal — Sensitivity 100% | Specificity 72.7% | Accuracy 87.0% | ROC-AUC 0.864
SCIENTIFIC COMMUNITY
Scientific Presentations
Liquid RNA research has been presented at ASCO GI 2026, ESMO TAT 2026, and the ASCO Annual Meeting 2026.
Observed results in cancer-specific research cohorts.
Molecular information that can prompt a closer look
In the ASCO GI 2026 retrospective study of 21 patients, cancer-related progression was identified 1–10 weeks before standard imaging (median: 5 weeks). Liquid RNA adds molecular information to support further investigation and discussions with your care team.
Liquid RNA is research-based and informational and complements standard imaging, pathology and physician-led care.
SAMPLE REPORT
See what a Liquid RNA report looks like
Review the structure, scope and type of molecular information included before deciding whether the test is right for you.
- Comprehensive mapping across a 20,814 gene transcriptions panel
- Structured insights into cancer-associated and broader biological pathways
- Clear, clinician-ready layout designed for review with your oncology care team
- Digital delivery provided in approximately three weeks from sample receipt
Research-based and informational. Liquid RNA complements, but does not replace, recommended clinical screening or oncology care.
REPORT STRUCTURE PREVIEW
Liquid RNA Analysis Report
20,814 active gene expression levels evaluated against cancer-associated reference datasets.
Evaluation of active immune, inflammatory, and cellular proliferation pathways.
Standardized comparative layout designed for repeat testing and trend assessment over time.
🔒 De-identified sample data • Approx. 3-week lab turnaround
CLINICAL CLARITY
Patient FAQ
Clear, objective guidance regarding the scope of liquid RNA sequencing, laboratory timelines, and how molecular data integrates into your ongoing clinical care.
Is Liquid RNA a diagnostic test?
No. It provides research-based molecular information and does not diagnose or rule out cancer.
Does it replace scans, pathology or routine screening?
No. It is additional information only.
Can it be used for treatment-response or recurrence monitoring?
It may add molecular context over time, but timing and interpretation should be discussed with an appropriate healthcare professional.
Can someone without a cancer diagnosis use it?
The report can explore cancer-associated and broader biological signals, but it is not a substitute for recommended screening.
How long do results take?
Approximately three weeks after the sample reaches the laboratory.
Can I see a sample report first?
Yes - use the enquiry form.
TRANSPARENT MOLECULAR TESTING
One comprehensive analysis
Liquid RNA provides a unified 20,814 gene transcription panel with full molecular reporting and coordinated sample collection logistics.
CANADA
C$5,300 + GST
Comprehensive 20,814 gene transcription panel analysis with coordinated Canadian blood-collection kit logistics.
UNITED STATES & INTERNATIONAL
US$3,900
Comprehensive 20,814 gene transcription panel analysis with coordinated sample transport and kit logistics.
Blood-collection or travel-related costs may vary depending on location. Confirm all costs before proceeding.
NO-OBLIGATION ENQUIRY
Start with a conversation,
not a commitment
Tell us what you hope to understand. We’ll explain the process, practical requirements and costs so you can decide whether Liquid RNA is appropriate for your goals.
Email: [email protected]
Phone: 778-999-5463, Extension 1
Live assistance: Monday–Friday, 8am–4pm Pacific
Start your enquiry
Tell us what you hope to understand. We’ll connect you with the right next step.
Research-based and informational. Liquid RNA complements—but does not replace—recommended screening, imaging, pathology, diagnosis or care from a licensed physician.